Effect of Daikenchuto (TU 100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 24 Jun 2016
At a glance
- Drugs TJ 100 (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- Sponsors Tsumura
- 07 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 23 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Aug 2015.
- 04 Jul 2013 New trial record